- Home
- MGNX vs GDL Comparison
MGNX vs GDL Comparison
Compare MGNX & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- GDL
- Stock Information
- Founded
- MGNX 2000
- GDL 2006
- Country
- MGNX United States
- GDL United States
- Employees
- MGNX N/A
- GDL N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- GDL Investment Managers
- Sector
- MGNX Health Care
- GDL Finance
- Exchange
- MGNX Nasdaq
- GDL Nasdaq
- Market Cap
- MGNX 114.2M
- GDL 94.2M
- IPO Year
- MGNX 2013
- GDL N/A
- Fundamental
- Price
- MGNX $1.66
- GDL $8.30
- Analyst Decision
- MGNX Hold
- GDL
- Analyst Count
- MGNX 9
- GDL 0
- Target Price
- MGNX $5.33
- GDL N/A
- AVG Volume (30 Days)
- MGNX 770.0K
- GDL 11.2K
- Earning Date
- MGNX 08-12-2025
- GDL 01-01-0001
- Dividend Yield
- MGNX N/A
- GDL 6.02%
- EPS Growth
- MGNX N/A
- GDL N/A
- EPS
- MGNX N/A
- GDL N/A
- Revenue
- MGNX $154,050,000.00
- GDL N/A
- Revenue This Year
- MGNX N/A
- GDL N/A
- Revenue Next Year
- MGNX N/A
- GDL N/A
- P/E Ratio
- MGNX N/A
- GDL N/A
- Revenue Growth
- MGNX 255.31
- GDL N/A
- 52 Week Low
- MGNX $0.99
- GDL $7.65
- 52 Week High
- MGNX $5.10
- GDL $8.13
- Technical
- Relative Strength Index (RSI)
- MGNX 51.94
- GDL 46.32
- Support Level
- MGNX $1.47
- GDL $8.21
- Resistance Level
- MGNX $1.64
- GDL $8.41
- Average True Range (ATR)
- MGNX 0.12
- GDL 0.05
- MACD
- MGNX -0.00
- GDL -0.01
- Stochastic Oscillator
- MGNX 26.83
- GDL 35.42
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.